Brief: Guerbet Receives EMA Acceptance Of Elucirem As The Brand Name For Gadopiclenol
June 13 (Reuters) - Guerbet SA GRBT.PA :
* GUERBET RECEIVES EMA ACCEPTANCE OF ELUCIREMTM AS THE BRAND
NAME
FOR GADOPICLENOL
* NO REGULATORY AUTHORITY HAS EVALUATED CLINICAL STUDY DATA
FOR
THIS PRODUCT TO DATE
* GADOPICLENOL IS AN INVESTIGATIONAL MACROCYCLIC
GADOLINIUM-BASED
CONTRAST AGENT
Source text for Eikon: ID:nGNE3000TM
Further company coverage: GRBT.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Guerbet SA
See all newsBrief: Guerbet Revenue At 30 September 2026 Of EUR 573.8 Million
Corrected: French medical imaging firm Guerbet's 9M revenue slips on China sales drop
French medical imaging firm Guerbet H1 EBITDA margin falls on Raleigh site costs
Brief: Guerbet H1 EBITDA €30.6 Mln
French and Benelux stocks-Factors to watch